Key Points
- Insider selling: Director Randall Moreadith sold a total of 17,500 Serina Therapeutics shares across four trades (Jan 21, Jan 22, Jan 28, Feb 2), totaling about $56,275, with the most recent sale of 6,500 shares on Feb 2 at $3.03 each.
- Stock and company context: SER opened at $2.76 and trades in a one‑year range of $1.71–$7.92; Serina is a biotech focused on neurological diseases and pain, with lead candidate SER‑252 targeting Parkinson’s disease.
Serina Therapeutics, Inc. (NYSEAMERICAN:SER - Get Free Report) insider Randall Moreadith sold 6,500 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $3.03, for a total value of $19,695.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Randall Moreadith also recently made the following trade(s):
- On Wednesday, January 28th, Randall Moreadith sold 6,500 shares of Serina Therapeutics stock. The shares were sold at an average price of $3.57, for a total value of $23,205.00.
- On Thursday, January 22nd, Randall Moreadith sold 2,500 shares of Serina Therapeutics stock. The stock was sold at an average price of $2.95, for a total value of $7,375.00.
- On Wednesday, January 21st, Randall Moreadith sold 2,000 shares of Serina Therapeutics stock. The shares were sold at an average price of $3.00, for a total value of $6,000.00.
Serina Therapeutics Stock Performance
Shares of Serina Therapeutics stock opened at $2.76 on Wednesday. Serina Therapeutics, Inc. has a 1 year low of $1.71 and a 1 year high of $7.92.
About Serina Therapeutics
(
Get Free Report)
Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
